Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 8/20 | 0.40 |
| ▸ | HTR2C | P28335 | 7/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15428695 | 0.81 | HTR2B (0.44) | HTR2AHTR2CJAK2JAK1 | |
| SCHEMBL403864 | 0.80 | CYP3A4 (0.46) | HTR2AHTR2CJAK2JAK1 | |
| SCHEMBL942635 | 0.76 | HTR2A (0.54) | RECQLHTR2AHTR2CKDM4ETDP1 | |
| SCHEMBL21500993 | 0.72 | HTR2A (0.43) | HTR2AHTR2CJAK2JAK1 | |
| SCHEMBL10823565 | 0.71 | SMN1; SMN2 (0.52) | KDM4ETDP1 | |
| SCHEMBL404089 | 0.69 | PRMT5 (0.46) | HTR2A | |
| SCHEMBL10725158 | 0.69 | SMN1; SMN2 (0.50) | KDM4ETDP1 | |
| SCHEMBL10333600 | 0.68 | RECQL (0.58) | RECQLABL1KDM4E | |
| SCHEMBL15973567 | 0.68 | HTT (0.53) | TDP1 | |
| SCHEMBL343083 | 0.68 | RECQL (0.50) | RECQLABL1KDM4ENOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150376196-A1 | 4-SUBSTITUTED PYRROLO- AND PYRAZOLO-DIAZEPINES | Bayer Pharma AG (DE) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376196-A1 | 4-SUBSTITUTED PYRROLO- AND PYRAZOLO-DIAZEPINES | BRDT, BRD4, BRD3 | RECQL 527/4885HTR2A 3532/4885HTR2C 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.